Cat# Name Description

Total Page:16

File Type:pdf, Size:1020Kb

Cat# Name Description Cat# Name Description D1 and D5 Receptors 1534 A 68930 hydrochloride Potent, selective D1-like agonist 0884 Dihydrexidine hydrochloride Selective D1-like agonist 0925 SCH 23390 hydrochloride Standard selective D1-like antagonist; also 5-HT2C and 5-HT1C agonist and Kir3 channel blocker 2299 SCH 39166 hydrobromide High affinity D1/D5 receptor antagonist 1447 SKF 81297 hydrobromide D1 agonist 2074 SKF 83959 hydrobromide D1-like partial agonist D2 Receptors 1003 L-741,626 High affinity D2 antagonist 1061 (-)-Quinpirole hydrochloride Selective D2-like agonist 5041 PAOPA Dopamine D2 receptor allosteric modulator 1810 Raclopride Potent, selective D2/D3 antagonist 3680 Ropinirole Selective D2-like agonist 2773 Sumanirole maleate D2-selective agonist D3 Receptors Dopamine 1847 Eticlopride hydrochloride Selective D2/D3 antagonist 1347 Nafadotride Highly potent, preferential D3 antagonist 1243 (+)-PD 128907 hydrochloride D3 agonist (D3 ≥ D2 > D4) 4174 Pramipexole dihydrochloride Selective D3 agonist 4207 SB 277011A dihydrochloride Selective D3 antagonist D4 Receptors 1002 L-745,870 trihydrochloride Highly selective D4 antagonist 2329 Ro 10-5824 dihydrochloride Selective D4 receptor partial agonist 1065 PD 168077 maleate High affinity, selective D4 agonist Dopamine Transporters 0421 GBR 12909 dihydrochloride Selective DA uptake inhibitor. Also σ ligand 1588 Indatraline hydrochloride Potent 5-HT uptake inhibitor; also inhibits dopamine and noradrenalin uptake Non-selective Dopamine 2073 (R)-(-)-Apomorphine hydrochloride Dopamine agonist; non-subtype-selective 3788 L-DOPA Dopamine precursor 2460 Lazabemide hydrochloride Selective MAO-B inhibitor 4395 Moclobemide Reversible MAO-A inhibitor Monoamine Oxidase 4308 Rasagiline mesylate Selective, irreversible MAO-B inhibitor 0723 Tetrindole mesylate MAO-A inhibitor 4720 Entacapone Potent COMT inhibitor; blocks α-synuclein aggregation Catechol O-methyltransferase 0483 OR-486 Catechol O -methyltransferase inhibitor 4534 CZC 54252 hydrochloride Potent LRRK2 inhibitor; neuroprotective LRRK2 4629 GSK2578215A Potent, selective LRRK2 inhibitor; brain penetrant 4273 LRRK2-IN-1 Potent and selective LRRK2 inhibitor 1063 CGS 21680 hydrochloride A2A agonist 5147 Istradefylline Potent and selective adenosine A2A receptor antagonist Adenosine A2A Receptors 4334 PSB 0777 ammonium salt Potent adenosine A2A agonist 2463 SCH 442416 Very selective, high affinity A2A antagonist 2270 SCH 58261 Potent, highly selective A2A antagonist 0455 (S )-(-)-Carbidopa Aromatic L-amino acid decarboxylase inhibitor Decarboxylases 0584 L-(-)-α-Methyldopa Aromatic L-amino acid decarboxylase inhibitor GABAA Receptors 0131 (-)-Bicuculline methochloride Water-soluble GABAA antagonist 1088 CGP 54626 hydrochloride Potent, selective GABAB antagonist GABA Receptors 1248 CGP 55845 hydrochloride Potent, selective GABAB antagonist 0289 Muscimol Potent, GABAA,GABAA-ρ receptor agonist 0984 SCH 50911 Selective, competitive and orally active GABAB antagonist 1262 SR 95531 hydrobromide Selective, competitive GABAA receptor antagonist Cat# Name Description NMDA Receptors 0106 D-AP5 Potent, selective NMDA antagonist 0173 (RS) -CPP Potent NMDA antagonist 1409 CGP 39551 Potent, selective and competitive NMDA antagonist 0545 Ifenprodil hemitartrate Non-competitive NMDA antagonist. Also σ ligand 0924 (+)-MK 801 maleate Non-competitive NMDA antagonist; acts at ion channel site 1594 Ro 25-6981 maleate NR2B-selective NMDA antagonist AMPK Receptors 0254 (S)-AMPA Selective AMPA agonist 0713 Cyclothiazide AMPA selective desensitization inhibitor 2766 Naspm trihydrochloride Ca2+-permeable AMPA receptor antagonist 0373 NBQX Potent AMPA antagonist 5032 Talampanel Non-competitive AMPA/kainate antagonist mGlu Group I Receptors 0805 (S) -3,5-DHPG Selective group I mGlu agonist Glutamate Receptors 2921 MTEP hydrochloride Potent, selective mGlu5 antagonist mGlu Group II Receptors 4048 BINA Selective positive allosteric modulator of mGlu 2 1209 LY 341495 Highly potent, selective group II antagonist 2453 LY 379268 Highly selective group II mGlu agonist mGlu Group III Receptors 0103 L-AP4 Selective group III mGlu agonist 2963 MMPIP hydrochloride Potent, allosteric mGlu7-selective antagonist 4371 VU 0364439 Positive allosteric modulator at mGlu 4 Kainate Receptors 2728 ACET Potent antagonist of GluR5-containing kainate receptors 3620 Topiramate GluR5 antagonist; inhibits carbonic anhydrase (CA) II and IV 0269 Domoic acid Potent, selective kainate agonist 2555 GYKI 53655 hydrochloride Kainate receptor antagonist; blocks GluK3 receptors 0903 SYM 2081 Highly selective kainate agonist 2079 UBP 302 Potent and selective kainate antagonist 5-HT1A Receptors 0529 8-Hydroxy-DPAT hydrobromide Selective 5-HT1A agonist 1253 (S)-WAY 100135 dihydrochloride Potent, selective 5-HT1A antagonist 4380 WAY 100635 maleate Potent, 5-HT1A silent antagonist. Also D4 agonist 5-HT1B Receptors 1477 GR 127935 hydrochloride Potent, selective 5-HT1B/1D antagonist 1242 SB 216641 hydrochloride Selective h5-HT1B antagonist 1221 SB 224289 hydrochloride Selective 5-HT1B antagonist 5-HT2A Receptors 0908 Ketanserin tartrate Selective 5-HT2A antagonist. Also antagonist at 5-HT 1D 4486 AT 1015 Long-acting 5-HT2A antagonist Serotonin Receptors 4470 EMD 281014 hydrochloride Selective 5-HT2A antagonist 4173 MDL 100907 Potent and selective 5-HT2A antagonist 2865 Risperidone 5-HT2A antagonist 2592 TCB-2 Potent, high affinity 5-HT2A agonist 5-HT2C Receptors 3041 CP 809101 hydrochloride Potent and selective 5-HT2C agonist 1007 N-Desmethylclozapine 5-HT2C antagonist 0941 MK 212 hydrochloride 5-HT2C agonist 1854 Ro 60-0175 fumarate Potent, selective 5-HT2C agonist 1050 RS 102221 hydrochloride Selective 5-HT2C antagonist 1801 WAY 161503 hydrochloride Potent, selective 5-HT2C agonist.
Recommended publications
  • Inhibition of 50-Khz Ultrasonic Vocalizations by Dopamine Receptor Subtype-Selective Agonists and Antagonists in Adult Rats
    Psychopharmacology (2013) 226:589–600 DOI 10.1007/s00213-012-2931-6 ORIGINAL INVESTIGATION Inhibition of 50-kHz ultrasonic vocalizations by dopamine receptor subtype-selective agonists and antagonists in adult rats Tina Scardochio & Paul B. S. Clarke Received: 6 September 2012 /Accepted: 13 November 2012 /Published online: 29 November 2012 # Springer-Verlag Berlin Heidelberg 2012 Abstract calling. The D4 agonist and antagonist did not significantly Rationale Adult rats emit ultrasonic calls at around 22 and affect 50-kHz call rates. Twenty-two-kilohertz calls oc- 50 kHz, which are often elicited by aversive and rewarding curred infrequently under all drug conditions. stimuli, respectively. Dopamine (DA) plays a role in aspects Conclusion Following systemic drug administration, tonic of both reward and aversion. pharmacological activation of D1-like or D2-like DA recep- Objective The purpose of this study is to investigate the tors, either alone or in combination, does not appear suffi- effects of DA receptor subtype-selective agonists on 22- cient to induce 50-kHz calls. Dopaminergic transmission and 50-kHz call rates. through D1, D2, and D3 receptors appears necessary for Methods Ultrasonic calls were recorded in adult male rats spontaneous calling. that were initially screened with amphetamine to eliminate low 50-kHz callers. The remaining subjects were tested after Keywords Vocalization . Dopamine receptor . Reward . acute intraperitoneal or subcutaneous injection of the fol- Aversion . Agonist . Antagonist . Reinforcement . lowing DA receptor-selective agonists and antagonists: Behavior . D1 [D-1] . D2 [D-2] A68930 (D1-like agonist), quinpirole (D2-like agonist), PD 128907 (D3 agonist), PD 168077 (D4 agonist), SCH 39166 (D1-like antagonist), L-741,626 (D2 antagonist), Introduction NGB 2904 (D3 antagonist), and L-745,870 (D4 antagonist).
    [Show full text]
  • Strategies for Managing Sexual Dysfunction Induced by Antidepressant Medication
    King’s Research Portal DOI: 10.1002/14651858.CD003382.pub3 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA): Taylor, M. J., Rudkin, L., Bullemor-Day, P., Lubin, J., Chukwujekwu, C., & Hawton, K. (2013). Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database of Systematic Reviews, (5). https://doi.org/10.1002/14651858.CD003382.pub3 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • Sex Differences in Nicotine-Conditioned Hyperactivity in a Model of Dopamine D2 Receptor Priming: Roles of Dopamine D2 and D3 Receptor Subtypes
    East Tennessee State University Digital Commons @ East Tennessee State University Electronic Theses and Dissertations Student Works 8-2008 Sex Differences in Nicotine-Conditioned Hyperactivity in a Model of Dopamine D2 Receptor Priming: Roles of Dopamine D2 and D3 Receptor Subtypes. Ashley Brianna Sheppard East Tennessee State University Follow this and additional works at: https://dc.etsu.edu/etd Part of the Hormones, Hormone Substitutes, and Hormone Antagonists Commons Recommended Citation Sheppard, Ashley Brianna, "Sex Differences in Nicotine-Conditioned Hyperactivity in a Model of Dopamine D2 Receptor Priming: Roles of Dopamine D2 and D3 Receptor Subtypes." (2008). Electronic Theses and Dissertations. Paper 1978. https://dc.etsu.edu/etd/ 1978 This Thesis - Open Access is brought to you for free and open access by the Student Works at Digital Commons @ East Tennessee State University. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Digital Commons @ East Tennessee State University. For more information, please contact [email protected]. Sex Differences in Nicotine-conditioned Hyperactivity in a Model of Dopamine D2 Receptor Priming: Roles of Dopamine D2 and D3 Receptor Subtypes A thesis presented to the faculty of the Department of Psychology East Tennessee State University In partial fulfillment of the requirements for the degree of Master of Arts in Psychology by Ashley Brianna Sheppard August 2008 Russell Brown, PhD., Chair Michael Woodruff, PhD., Committee member Otto Zinser,
    [Show full text]
  • Designing Inhibitors Via Molecular Modelling Methods for Monoamine Oxidase Isozymes a and B Filiz Varnali Kadir Has Universit
    DESIGNING INHIBITORS VIA MOLECULAR MODELLING METHODS FOR MONOAMINE OXIDASE ISOZYMES A AND B FİLİZ VARNALI KADİR HAS UNIVERSITY 2012 DESIGNING INHIBITORS VIA MOLECULAR MODELLING METHODS FOR MONOAMINE OXIDASE ISOZYMES A AND B FİLİZ VARNALI M.S. in Computational Biology and Bioinformatics, Kadir Has University, 2012 Submitted to the Graduate School of Science and Engineering in partial fulfilment of the requirements for the degree of Master of Science in Computational Biology and Bioinformatics KADİR HAS UNIVERSITY 2012 DESIGNING INHIBITORS VIA MOLECULAR MODELING METHODS FOR MONOAMINE OXIDASE ISOZYMES A AND B Abstract In drug development studies, a large number of new drug candidates (leads) have to be synthesized and optimized by changing several moieties of the leads in order to increase efficacies and decrease toxicities. Each synthesis of these new drug candidates include multi-steps procedures. Overall, discovering a new drug is a very time-consuming and very costly works. The development of molecular modelling programs and their applications in pharmaceutical research have been formalized as a field of study known computer assisted drug design (CADD) or computer assisted molecular design (CAMD). In this study, using the above techniques, Monoamine Oxidase isozymes, which play an essential role in the oxidative deamination of the biogenic amines, were studied. Compounds that inhibit these isozymes were shown to have therapeutic value in a variety of conditions including several psychiatric and neurological as well as neurodegenerative diseases. First, a series of new pyrazoline derivatives were screened using molecular modelling and docking methods and promising lead compounds were selected, and proposed for synthesis as novel selective MAO-A or –B inhibitors.
    [Show full text]
  • Pharmacological Stimulation of Brain Dopamine D3 Receptors Induced
    ABSTRACT Pharmacological stimulation of brain dopamine D3 receptors induced ejaculation in anaesthetised rats # 163 Pierre Clément 1, Jacques Bernabé 1, Laurent Alexandre 1, François Giuliano 1,2 * 1PELVIPHARM Laboratories, Gif-sur-Yvette, France 2Raymond Poincaré Hospital, Neuro-Urology Unit, Garches, France * e-mail address: [email protected] ABSTRACT INTRODUCTION & OBJECTIVE RESULTS Introduction and Objective : We have previously found that intracerebroventricular (i.c.v.) Ejaculation consists in two distinct and successive phases i.e. emission and expulsion with the latter caused Figure 1 . Sample of EMG recording of the injection of the non selective dopamine D2/D3 receptors agonist by rhythmic contractions of pelvic floor striated muscles; the primary role being played by bulbospongiosus 7-OH-DPAT i.c.v. bulbospongiosus (BS) muscles obtained in quinelorane induced rhythmic (BS) muscles (Gerstenberg et al., 1990). (1 µg) anaesthetised rats after i.c.v. delivery of 7- contractions of bulbospongiosus 10 s (BS) muscles, which is key for OH-DPAT (1 µg). expelling semen out the urethra, in anaesthetised rats. In the present We have previously reported that the dopamine D2-like receptor agonist quinelorane delivered in cerebral A magnification of the tracing of BS-EMG is study we aimed at demonstrating ventricle was capable to elicit rhythmic BS muscles contractions in anaesthetised rats (Clement et al., 2006; displayed in the inset and allows to see the which of these dopamine receptor subtypes is involved in triggering BS EAU 2006, poster #164). In addition it has been shown that the preferential D3 receptor agonist 7-OH-DPAT V unitary events (i.e.
    [Show full text]
  • Subject Index
    Subject Index A 68930 130 appetitive Conditions 81 A 86929 130 arachidonic acid 185,223 acetylcholine (ACh) 9 arcuate nucleus 89,97 acoustic neurinoma 227 aripiprazole 36 ACTH, see Adrenocortcotropic asynaptic release 100 hormone 173 ATF1, see Activating transcription factor activating transcription factor 1 (ATF 1) 1 326 attention 276 adaptive reponses 321 attention deficit hyperactivity disorder adenosine A2A receptor 164 (ADHD) 278 adenosine triphosphatase 269, 306 autism 128 adenylyl cyclase 11, 121, 163, 185, 236 autoreceptor 34 ADHD, see attention deficit aversive conditions 81 hyperactivity disorder adrenal gland 173 basal ganglia 31,166,310 adrenal medullary hormones 25 bed nucleus 55 adrenocorticotropic hormone (ACTH) benzazepine 130, 140 173 benzonaphtazepine 131 aggression 276 benztropine 270 akinesia 167 beta (~) adrenoreceptor 10, 238 alcohol 33, 169,203 beta (~)-arrestin 135 alpha (a)olf protein 237 beta (~)-endorphin 173 alpha (a)receptor adrenergic 10 biogenic amines 29 alpha's protein 237 bipolar cell 92 alpha-(a) melanocyte stimulating bipolar disorder 127,227 hormone (a-MSH) 171 bradykinesia 167 alpha-(a) methyltyrosine 33 brain development 201 amacrine cells 92 brain-derived neurotrophic factor amineptine 206 (BDNF) 187 aminotetralin 195 bromocriptine 12, 171, 309 amisulpride 196 brown adipose tissue 243 amitriptyline 206 buproprion 206 AMPA receptor channels 333 butaclamol 125,131 amperozide 196 amphetamine 12,33,135, 169,270,276, calbindin (CaBP) 44,87 325 calcineurin 244 amphetamine stereoselectivity 262 calcium
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0052435 A1 Van Der Graaf Et Al
    US 20060052435A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0052435 A1 Van der Graaf et al. (43) Pub. Date: Mar. 9, 2006 (54) SELECTIVE DOPAMIN D3 RECEPTOR (86) PCT No.: PCT/GB02/05595 AGONSTS FOR THE TREATMENT OF SEXUAL DYSFUNCTION (30) Foreign Application Priority Data (76) Inventors: Pieter Hadewijn Van der Graaf, Dec. 18, 2001 (GB) - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - O1302199 County of Kent (GB); Christopher Peter Wayman, County of Kent (GB); Publication Classification Andrew Douglas Baxter, Bury St. Edmunds (GB); Andrew Simon Cook, (51) Int. Cl. County of Kent (GB); Stephen A6IK 31/405 (2006.01) Kwok-Fung Wong, Guilford, CT (US) (52) U.S. Cl. .............................................................. 514/419 Correspondence Address: (57) ABSTRACT PFIZER INC. PATENT DEPARTMENT, MS8260-1611 The use of a composition comprising a Selective dopamine EASTERN POINT ROAD D3 receptor agonist, wherein Said dopamine D3 receptor GROTON, CT 06340 (US) agonist is at least about 15-times more functionally Selective for a dopamine D3 receptor as compared with a dopamine (21) Appl. No.: 10/499,210 D2 receptor when measured using the same functional assay, in the preparation of a medicament for the treatment and/or (22) PCT Filed: Dec. 10, 2002 prevention of Sexual dysfunction. Patent Application Publication Mar. 9, 2006 Sheet 1 of 2 US 2006/0052435 A1 Figure 1 A Selective D3 agonist provides a significant therapeutic window between prosexual and dose-limitind side effects Apomorphine EHV VE - vomiterection D27.2nMD33.9nM E HV H - hypotension O3 0.56nM Log Free plasma O. 1.0 O 1OO 1OOO conc (nM) D3D24973M agonist E noH noV D2 adOnist D2 ag Conclusion D3 No effect D2 & D3 mediates erection D2 mediates vomiting/hypotension Patent Application Publication Mar.
    [Show full text]
  • Antipsychotic Drugs Influence Dopamine Neuron Terminals Via Action on D2‐Receptors and Vesicles
    Antipsychotic Drugs Influence Dopamine Neuron Terminals via Action on D2‐receptors and Vesicles Alex Klausing Honors Thesis in the Pharmaceutical Sciences Major College of Pharmacy The Ohio State University Advisor: Lane J. Wallace Spring 2013 Abstract Dopamine D2 antagonist antipsychotic drugs share the effects of increasing dopamine synthesis, dopamine neuron firing rate, and dopamine and DOPAC levels. These antagonists all raise extracellular dopamine to approximately 163% of control and DOPAC levels to approximately 200% of control without changing tissue level of dopamine. Variability in striatal tissue DOPAC level (190 – 350% of control) and rates of dopamine synthesis (190‐378% of control) reported after administration of various antipsychotic drugs gives evidence that these parameters are influenced by factors besides the antagonism of the D2 receptor. We used a computational model of dopaminergic terminals in the striatum to determine what parameters other than D2 receptors might be targets for the drugs. Simulation model results suggest that D2 receptor antagonism results in a slight increase in rate of dopamine exocytosis accompanied by a small increase in rate of dopamine synthesis needed to maintain the increase in rate of exocytosis and a small increase in rate of dopamine synthesis specifically dedicated to DOPAC secretion. Simulation model results also suggest that variable increases in levels of tissue DOPAC result from increases in passive diffusion of dopamine out from vesicles coupled with an increase in rate of dopamine synthesis required to maintain tissue levels of dopamine. Biochemical data reported in the literature suggests changes in passive diffusion depend on the ability of the antipsychotic drug to diffuse into and alkalinize vesicles.
    [Show full text]
  • Parkinson's Disease Quality Measurement Set Update
    Parkinson’s Disease Quality Measurement Set Update Approved by the Parkinson’s Disease Update Quality Measurement Development Work Group on September 3, 2015, by the AAN Quality and Safety Subcommittee on September 23, 2015; by the AAN Practice Committee on October 19, 2015; and by the AANI Board of Directors on November 5, 2015. ©2015. American Academy of Neurology. All Rights Reserved. 1 CPT Copyright 2004-2013 American Medical Association. Disclaimer Performance Measures (Measures) and related data specifications developed by the American Academy of Neurology (AAN) are intended to facilitate quality improvement activities by providers. AAN Measures: 1) are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications; 2) are not continually updated and may not reflect the most recent information; and 3) are subject to review and may be revised or rescinded at any time by the AAN. The measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes (e.g., use by health care providers in connection with their practices); they must not be altered without prior written approval from the AAN. Commercial use is defined as the sale, license, or distribution of the measures for commercial gain, or incorporation of the measures into a product or service that is sold, licensed, or distributed for commercial gain. Commercial uses of the measures require a license agreement between the user and the AAN. Neither the AAN nor its members are responsible for any use of the measures. AAN Measures and related data specifications do not mandate any particular course of medical care and are not intended to substitute for the independent professional judgment of the treating provider, as the information does not account for individual variation among patients.
    [Show full text]
  • Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders
    biomolecules Review Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders Béla Kiss 1, István Laszlovszky 2, Balázs Krámos 3, András Visegrády 1, Amrita Bobok 1, György Lévay 1, Balázs Lendvai 1 and Viktor Román 1,* 1 Pharmacological and Drug Safety Research, Gedeon Richter Plc., 1103 Budapest, Hungary; [email protected] (B.K.); [email protected] (A.V.); [email protected] (A.B.); [email protected] (G.L.); [email protected] (B.L.) 2 Medical Division, Gedeon Richter Plc., 1103 Budapest, Hungary; [email protected] 3 Spectroscopic Research Department, Gedeon Richter Plc., 1103 Budapest, Hungary; [email protected] * Correspondence: [email protected]; Tel.: +36-1-432-6131; Fax: +36-1-889-8400 Abstract: Dopamine (DA), as one of the major neurotransmitters in the central nervous system (CNS) and periphery, exerts its actions through five types of receptors which belong to two major subfamilies such as D1-like (i.e., D1 and D5 receptors) and D2-like (i.e., D2, D3 and D4) receptors. Dopamine D3 receptor (D3R) was cloned 30 years ago, and its distribution in the CNS and in the periphery, molecular structure, cellular signaling mechanisms have been largely explored. Involvement of D3Rs has been recognized in several CNS functions such as movement control, cognition, learning, reward, emotional regulation and social behavior. D3Rs have become a promising target of drug research and great efforts have been made to obtain high affinity ligands (selective agonists, partial agonists and antagonists) in order to elucidate D3R functions. There has been a strong drive behind the efforts to find drug-like compounds with high affinity and selectivity and various functionality for D3Rs in the hope that they would have potential treatment options in CNS diseases such as schizophrenia, drug abuse, Parkinson’s disease, depression, and restless leg syndrome.
    [Show full text]
  • Discrimination Between Mechanism-Based Inactivation and Tight Binding Inhibitor Behavior
    Biomedical Chemistry: Research and Methods 2020, 3(1), e00115. DOI: 10.18097/bmcrm00115 1 EXPERIMENTAL RESEARCH A SIMPLE APPROACH FOR PILOT ANALYSIS OF TIME-DEPENDENT ENZYME INHIBITION: DISCRIMINATION BETWEEN MECHANISM-BASED INACTIVATION AND TIGHT BINDING INHIBITOR BEHAVIOR O.A. Buneeva, L.N. Aksenova, A.E. Medvedev* Institute of Biomedical Chemistry, 10 Pogodinskaya str., Moscow, 119121 Russia; *e-mail: [email protected] The increase in enzyme inhibition developed during prolonged incubation of an enzyme preparation with a chemical substance may be associated with both the non-covalent and also with covalent enzyme-inhibitor complex formation. The latter case involves catalytic conversion of a mechanism-based irreversible inhibitor (a poor substrate) into a reactive species forming covalent adduct(s) with the enzyme and thus irreversibly inactivating the enzyme molecule. Using a simple approach, based on comparison of enzyme inhibition after preincubation with a potential inhibitor at 4ºC or 37ºC we have analyzed inhibition of monoamine oxidase A (MAO A) by known MAO inhibitors pargyline and pirlindole (pyrazidol). MAO A inhibitory activity of pirlindole (reversible tight binding inhibitor of MAO A) assayed after mitochondrial wash was basically the same for the incubation at both 4ºC and 37ºC. In contrast to pirlindole, the effect of pargyline (mechanism based irreversible MAO inhibitor) strongly depended on the temperature of the incubation medium. At 37ºC the residual activity MAO A in the mitochondrial fraction after washing was significantly lower than in the mitochondrial samples incubated with pargyline at 4ºC. Results of this study suggest that using analysis of both time- and temperature-dependence of inhibition it is possible to discriminate mechanism-based irreversible inhibition and reversible tight binding inhibition of target enzym Key words: enzyme inhibition; time-dependent and temperature-dependent inhibition; mechanism-based inhibitors; reversible tight binding inhibitors DOI: 10.18097/BMCRM00115 INTRODUCTION (England).
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]